Submit Manuscript  

Article Details


Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop

[ Vol. 18 , Issue. 1 ]

Author(s):

Ramesh Akkina, Daniel L. Barber, Moses T. Bility, Karl-Dimiter Bissig, Benjamin J. Burwitz, Katrin Eichelberg, Janice J. Endsley, J. Victor Garcia, Richard Hafner, Petros C. Karakousis, Brent E. Korba, Rajen Koshy, Chris Lambros, Stephan Menne, Eric L. Nuermberger, Alexander Ploss, Brendan K. Podell, Larisa Y. Poluektova, Brigitte E. Sanders-Beer*, Selvakumar Subbian and Angela Wahl   Pages 19 - 28 ( 10 )

Abstract:


The main advantage of animal models of infectious diseases over in vitro studies is the gain in the understanding of the complex dynamics between the immune system and the pathogen. While small animal models have practical advantages over large animal models, it is crucial to be aware of their limitations. Although the small animal model at least needs to be susceptible to the pathogen under study to obtain meaningful data, key elements of pathogenesis should also be reflected when compared to humans. Well-designed small animal models for HIV, hepatitis viruses and tuberculosis require, additionally, a thorough understanding of the similarities and differences in the immune responses between humans and small animals and should incorporate that knowledge into the goals of the study. To discuss these considerations, the NIAID hosted a workshop on ‘Small Animal Models for HIV, Hepatitis B, and Tuberculosis’ on May 30, 2019. Highlights of the workshop are outlined below.

Keywords:

HIV, AIDS, co-infections, HBV, tuberculosis, animal models.

Affiliation:

Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania, Department of Pediatrics, Duke University, Durham, North Carolina, Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, North Carolina, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, Division of Infectious Diseases, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, Department of Microbiology & Immunology, Georgetown University, Washington, DC, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, Department of Microbiology & Immunology, Georgetown University, Washington, DC, Division of Infectious Diseases, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, Department of Molecular Biology, Princeton University, Princeton, New Jersey, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, Department of Pharmacology and Experimental Neuroscience and Translational Mouse Model Core Facility, University of Nebraska Medical Center, Omaha, Nebraska, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, The Public Health Research Institute Center of New Jersey Medical School, Rutgers University, Newark, New Jersey, Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, North Carolina

Graphical Abstract:



Read Full-Text article